Description: Context Therapeutics Inc., is a women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The company’s robust clinical program for lead candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women’s cancers. Context is headquartered in Philadelphia, PA. For more information, visit www.contexttherapeutics.com.
Industry: Biotechnology
Website: http://www.contexttherapeutics.com
Company size: 1-10 employees
XRD rank: 3052905
Headquarter: Philadelphia, PA
Ownership: Private company
Founded year: 2015
Skillset: Oncology, Sigma1, Breast Cancer, Apristor, and Onapristone
Crunchbase profile: –
Funding rounds total: –
Selected investors: –
Location: –